Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Insulet Corporation ( NASDAQ:PODD ) saw a double-digit share price rise of over 10% in the past couple of months on ...

Inspire Medical Systems shows improving price performance, earning an upgrade to its IBD Relative Strength Rating ...

Bank of America Securities analyst Travis Steed maintained a Buy rating on Insulet (PODD – Research Report) yesterday and set a price target of ...

Buying $100 In PODD: If an investor had bought $100 of PODD stock 10 years ago, it would be worth $598.02 today based on a ...

TD Cowen raised the firm’s price target on Insulet (PODD) to $324 from $264 and keeps a Buy rating on the shares. The firm thinks Insulet will ...

Valued at a market cap of $18.5 billion, Insulet Corporation (PODD) develops, manufactures, and sells insulin delivery ...

Insulet (NASDAQ:PODD – Get Free Report) had its target price increased by investment analysts at TD Cowen from $264.00 to ...

Insulet develops, manufactures, and markets the Omnipod Insulin Management System for those with Type 2 diabetes. The system ...

BTIG raised the firm’s price target on Insulet (PODD) to $300 from $270 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models in select Medical Technology ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An ...

Insulet Corp. closed $14.65 short of its 52-week high ($279.77), which the company reached on December 12th.